Pharmaceutical Executive January 2013

January 2013 | Volume 0, Issue 0
From the Editor
2013 may be a number associated with the fate of the luckless, but our annual review of the business and policy environment for Big Pharma suggests otherwise—as we near the midway point in the "tween" decade, there is good fortune in store for those with the perspective that comes with the long view.
As companies seek safety from empowered payers, bankrupt governments, and distracted regulators, success will come to those who understand how competition and technology are changing the way everything this industry does.
New research sheds fresh light on a trend with serious consequences for the public health—not only in the United States but for patients worldwide.
By Pharmaceutical Executive Editors
Compliance officers have risen into management's highest ranks, by choice in some organizations, and by government decree in others. Either way, their importance as a strategic partner can hardly be understated.
By Pharmaceutical Executive Editors
Promoting the merits of private-sector drug innovation is no easy task—just ask the UK's Office of Health Economics, with a record 50 years of engagement around the hard policy questions that ultimately drive success in the pharmaceutical marketplace.
Country Report
By Pharmaceutical Executive Editors
Most executives across the pharmaceutical industry agree—Singapore does not represent any question marks in the future. Furthermore, Singapore's location is ideal for reaching markets east, west, north and south, which form the powerhouse that is Asia-Pacific.
By Pharmaceutical Executive Editors
Courts across the country are making it easier to prove that a drug is unsafe, warning label notwithstanding.
By Pharmaceutical Executive Editors
Don't underestimate the importance of the first line manager.
Thankfully, the civil war is not a public relations issue for Big Pharma, but the long-term business implications for the Middle East region are cagey.
By Pharmaceutical Executive Editors
Doctor-patient conversations aren't always what we think—this basic interaction represents both a problem and an opportunity for today's drug marketers, writes Al Topin.
FDA policies will reshape drug development, while pressure to cut healthcare spending may alter drug coverage and pricing.
lorem ipsum